[6] Through its Product Development Partnership (PDP), Sabin has worked with organizations such as King Saud University,[7] Texas Children's Hospital Center,[8] International Vaccine Institute,[9] and George Washington University School of Medicine & Health Sciences[10] toward its goals, with funding and support from the Bill & Melinda Gates Foundation,[10][11] the National Institute of Allergy and Infectious Diseases,[12] the Dutch Ministry of Foreign Affairs,[13] the Brazilian Ministry of Health[13] and other benefactors.

In 2012, Sabin partnered with International Vaccine Institute to combine their research, development, and promotion efforts in Asia, Africa, and the Americas.

[9] Sabin is currently working on multiple vaccines for humans[1] including vaccines for Hookworm infection (Na-GST-1, Na-APR-1),[10][13][14][15] Schistosomiasis (Sm-TSP-2),[16][17][18][19] Chagas disease (Tc24, TSA-1),[8][20][21] Leishmaniasis (Ld-NH36, PdSP15),[22][23][24] severe acute respiratory syndrome (SARS)/Middle East respiratory syndrome (MERS) (Pan-β-CoVax),[25][26][27] Soil-transmitted helminthiasis (STH),[28][29] and Onchocerciasis (Ov-103, Ov-RAL-2).

[30][31][32][33] In 2006, Sabin co-founded the Global Network for Neglected Tropical Diseases in order "to raise the awareness, political will and funding necessary to control and eliminate the most common NTDs.

"[35] Sabin works with experts and organizations from around the world to advance knowledge of both infectious diseases and the vaccines that can prevent them.